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 Milan, December 10th, 2015 
 
Dear Dr Robertson, 
 
 hereby, I kindly ask you to evaluate the revised version of our manuscript JC-15-3403 
for publication in JCEM as an Original Article. 
The title of the manuscript is “JAG1 loss-of-function variations as a novel 
predisposing event in the pathogenesis of congenital thyroid defects”. 
The authors of the manuscript are: Tiziana de Filippis, Federica Marelli, Gabriella 
Nebbia, Patrizia Porazzi, Sabrina Corbetta, Laura Fugazzola, Roberto Gastaldi, Maria Cristina 
Vigone, Roberta Biffanti, Daniela Frizziero, Luana Mandarà, Paolo Prontera, Mariacarolina 
Salerno, Mohamad Maghnie, Natascia Tiso, Giorgio Radetti, Giovanna Weber and Luca 
Persani. 
We were delighted to read the positive comments of the Reviewers. In this revision, 
we made a series of novel experiments that were asked by the Reviewer 1 in order to 
demonstrate the specificity and improve the quality of our jag1a/b gene knock-down in the 
zebrafish. We believe that we addressed all the comments raised and provide enclosed a 
rebuttal illustrating all the changes that were made into our manuscript. We also included a 
structured abstract. The revised text was highlighted in yellow all along the revised 
manuscript. We believe that the manuscript has significantly improved and  provides data 
supporting JAG1 gene variations as a novel predisposing factor in the pathogenesis of thyroid 
defects, including congenital hypothyrodism.  
All the Authors approved the revised version of this manuscript. On behalf of all 
Authors, I declare no conflict interest related to this work. 
 
I hope that you will find our revised manuscript worthy for consideration, and look forward 
your decision. 
 
 
Sincerely yours, 
 
 
Luca Persani, MD, PhD 
Corresponding Author 
 
 
 
 
Cover Letter
Reviewers' comments: 
 
Reviewer #1: Filippis and colleagues describe the identification of alterations in Jagged1 as a predisposing 
event in the pathogenesis of congenital thyroid defects. Building off their prior work identifying a role for 
jag1a and jag1b in thyroid development in zebrafish, they analyze the role of Jagged1 in the pathogenesis 
of congenital thyroid defects in human disease. They find an association between ALGS1 patients and non-
autoimmune hypothyroidism. They identify features of non-autoimmune mild hypothyroidism in 6/21 ALGS 
patients, and in 2/6 of these patients thyroid hypoplasia. The authors identify two variants in JAG1 in 4/100 
patients with congenital hypothyroidism. They perform subcellular localization of JAG1 variants in NIH-3T3 
cells by overexpression and immunofluorescence. They test the variants in a functional assay for 
differentiation of C2C12 myoblasts.  
 
The authors use a functional assay in zebrafish to determine the consequence of expressing JAG1 variants. 
The authors perform morpholino based knockdown, using previously published morpholinos targeting 
jag1a and jag1b and determine the consequence on global developmental morphology and thyroid 
differentiation markers. This is not terribly novel in light of their prior published work (Porazzi, 
Endocrinology 2012), though they do look at combined knockdown in this study and look at markers by 
confocal, which is new. 
R.: The experiments here performed show for the first time the results of the combined knock-down of both 
jag1a/b genes in zebrafish. In addition to the determination of thyroid markers we also show for the first 
time the results of an increased tshba expression after jag1a/b silencing, a figure that definitely confirm the 
generation of a primary thyroid defect.  
 
The authors compare the efficiency of wild-type human JAG1 and variants they identify in a zebrafish based 
rescue assay. This critical data is not totally convincing to me. In Fig 4 panel A, the histogram labeling and 
figure legend is unclear. What exactly was injected?  
R.: We thank the reviewer for highlighting this. We made more clear the legend of the figure and we 
clarified the different experimental conditions under the X axis. 
If it is each variant alone then the '+' is misleading. In Fig. 4 panel B the ability of wild-type vs. variant JAG1 
isoforms is compared. Why are such large numbers of embryos needed to make this point?  
R. The advantage of this model animal is the possibility to evaluate a large number of samples at the same 
time. This allows the possibility to confer a significant impact to variations that in other models or assays 
are hard or more expensive to obtain. 
This would be more convincing if the authors showed representative examples and specific markers. The 
authors perform a reporter assay using an NICD reporter in zebrafish. This demonstrates functional 
differences between Jag1 variants in an in vivo reporter gene assay in zebrafish. 
 
Major points: 
 
Recently significant issues related to morpholino specificity have been highlighted as a major concern in 
zebrafish genetic studies (Kok, et al Developmental Cell Jan 2015). Many investigators are shifting to 
genome editing using CrispR/Cas9 for this reason. In this manuscript the authors use previously tested 
morpholinos targeting jag1a/1b. My main concern is that the evidence that these reagents rigorously 
Point-by-Point Rebuttal
knockdown jag1a/1b expression may not be as strong as desirable. The minimum data needed to validate 
these tools would include: 
R: We thank the reviewer for this comment. Indeed, we are aware of the risk associated with the use of 
morpholinos, as with other different genetic manipulations. We indeed, verified that our morpholinos 
induced specific knock-down effects. Of note, in the original paper on the perturbation of Notch pathway 
and consequent effects on thyroid development in zebrafish (Porazzi et al. “Disruption of global and JAG1-
mediated Notch signaling affect thyroid morphogenesis in the zebrafish” that was published In 
Endocrinology 2012; ref 6 in this manuscript) we tested by RT-qPCR the effects obtained on jag1a and jag1b 
by morpholino knock-down, and in the case of jag1b also by analysis of the zebrafish jag1bb1105 mutant line. 
The thyroid phenotype was indeed similar in jag1b morphants and mutants confirming the specificity of 
jag1b knock-down. 
 
1. Demonstrate targeting of the splice junction by RT-qPCR for each morpholino separately. 
R1. This issue was previously investigated in the reference 6. In the supplemental Figure 4 of re.  6, we 
showed the specific morpholino-mediated knock-down of jag1a and jag1b, separately. The Legend of Figure 
2 was revised and includes this information. 
 
2. Demonstrate that combining the morpholinos targets both genes by qPCR 
R2. The effects of the combined knock-down on jag1a and jag1b expression (by semi-quantitative and 
quantitative RT-PCR) by means of the co-injection of both morpholinos are now shown in Figure 2, panels B, 
C, D. The efficiency of the combined knock-down was similar to that seen for each morpholino separately 
(see supplemental fig 4 of ref 6).  
 
3. Explore whether there is an antibody that can be used to measure jag1a/b levels in zebrafish.  
R3. Antibodies against Jag1 are indeed available but made against human or mouse jag1 proteins. We 
indeed had tested several of  these antibodies but the results were quite deceiving as none of them gave 
reliable results in the zebrafish. 
 
4. Provide higher quality images of JAG1 rescued morphants. 
R4: We thank the reviewer for this criticism. We provide a revised Figure 4, that includes new panels with 
images of improved quality and  illustrating the rescue phenotypes in more details. The legend of Figure 4 
was also revised accordingly. 
 
5. Include an analysis of thyroid marker genes by whole mount in situ after JAG1 rescue.  
R5: The revised Figure 4 now includes  panels  G-L that show the thyroglobulin expression (lateral and 
ventral views) in the control fish and in the rescued vs non-rescued zebrafish morphants. Note that rescued 
morphants exhibit a normal thyroid morphology and volume at 72 hrs.  
 6. The authors bin the morpholino phenotypes into (3) classes which correlate nicely with thyroid marker 
expression. They need to correlate these phenotypes with the efficiency of morpholino knockdown using a 
molecular assay. 
R6. We thank the reviewer for the suggestion. In the revised figure 2 (panels C, D) we correlated the 
observed phenotype classes with the efficiency of jag1a/b knock-down. Indeed, the severity degree of the 
phenotype was correlated with a more profound knock-down of jag1a/b. Indeed, a more profound knock-
down of jag1b was associated with an early lethality (<24 hrs).  
 
Minor Points 
 
1. Fig 4A histogram and legend is unclear. See above. 
R. This  figure and legend were completely revised, accordingly (see R4 and R5) 
 
 
Reviewer #2: The authors investigated the role of JAG1 in congenital hypothyroidism. Assisted by several 
institutions within Italy, 100 unrelated subjects with congenital hypothyroidism were investigated as well as 
21 patients with ALGS1 syndrome. Six of the 21 individuals with ALGS1 were found to have various degrees 
of hypothyroidism and of the 100 patients with congenital hypothyroidism, 4 were found to have a variant 
JAG1.  
 
CRITIQUE 
 
The authors provide a detailed study of their cohort, both in terms of clinical information as well as in vitro 
and in zebra fish, studies to better characterize the putative pathogenicity of these variants. 
 
The studies were well conducted. It is interesting that inheritance was paternal in 4 cases and maternal in 
2. However, the samples are too small to draw conclusions. 
R: We thank the Reviewer for the positive comments. Indeed, we cannot draw conclusion on sex-related 
pattern of inheritance due to the limited size of the sample. However, these data provide clues against the 
possible involvement of parental imprinting.   
 The authors have a tendency to dramatize the effect of the JAG1 variants. More specifically, in the 
summary of in silico prediction of the JAG1 variants effect (Supplemental Table 2), R744Q is listed as 
"damaging" for SIFT and "possibly damaging" for polyphen2 when the scores in ensembl are 0.06 and 
0.086, respectively, both tolerated. 
R: We thank the Reviewer for this information. Due to the awareness on the limited value of the in silico 
prediction, we indeed tested the missense/truncated/frameshift variants by means of 7 different algorithms 
and, in order to avoid bias due the choice of one specific prediction algorithm, we gave a summary of the 
deleterious predictions in the supplemental Table 2.  
Of note, we indeed interrogated  the different algorithms, including SIFT and PolyPhen-2, through an 
updated professional software (Alamut Visual 2.4) and not through the public available version of these two 
algorithms on ENSEMBL. Different versions of the prediction algorithms may explain such discrepancy. In 
fact, on the website of ENSEMBL it is clearly stated that: “Different versions of the protein databases can 
result in substantial variance  in the predictions and scores obtained. ENSEMBL releases are not 
synchronized with updates to the SIFT and PolyPhen webservers, so differences are to be expected”.  This is 
indeed another argument  supporting the use of various algorithms for the prediction on the damaging 
effect of one gene variant. 
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 Abstract 40 
Context: The pathogenesis of congenital hypothyroidism (CH) is still largely unexplained. We 41 
previously reported that perturbations of the Notch pathway and knockdown of the ligand jagged1 42 
cause a hypothyroid phenotype in the zebrafish. Heterozygous JAG1 variants are known to account 43 
for Alagille syndrome type 1 (ALGS1), a rare multisystemic developmental disorder characterized 44 
by variable expressivity and penetrance. 45 
Objective: Verify the involvement of JAG1 variants in the pathogenesis of congenital thyroid 46 
defects and the frequency of unexplained hypothyroidism in a series of ALGS1 patients. 47 
Design, Settings, Patients: A total of 21 young ALGS1 and 100 CH unrelated patients were 48 
recruited in academic and public hospitals. The JAG1 variants were studied in vitro and in the 49 
zebrafish. 50 
Results: We report a previously unknown non-autoimmune hypothyroidism in 6/21 ALGS1 51 
patients, 2 of them with thyroid hypoplasia. We found two JAG1 variants in the heterozygous state 52 
in 4/100 CH cases (3 with thyroid dysgenesis, 2 with cardiac malformations). Five out 7 JAG1 53 
variants are new. Different bioassays demonstrate that the identified variants exhibit a variable loss-54 
of-function. In zebrafish, the knock-down of jag1a/b expression causes a primary thyroid defect, 55 
and rescue experiments of the hypothyroid phenotype with wild-type or variant JAG1 transcripts 56 
support a role for JAG1 variations in the pathogenesis of the hypothyroid phenotype seen in CH and 57 
ALGS1 patients.  58 
Conclusions: clinical and experimental data indicate that ALGS1 patients have an increased risk of 59 
non-autoimmune hypothyroidism, and that variations in JAG1 gene can contribute to the 60 
pathogenesis of variable congenital thyroid defects, including CH.  61 
  62 
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Introduction 63 
Congenital hypothyroidism (CH) is the most common endocrine developmental disorder and 64 
preventable cause of mental retardation. In recent years, several groups from various socio-65 
economically developed countries described a tendency toward an increased CH incidence (about 1 66 
out 1500-2000 newborns) (1-3). Both functional and developmental defects can account for CH but 67 
its etiology is still poorly understood (4,5). Genetic defects are believed to be frequently involved, 68 
but the disease is generally reported to be sporadic and variations in candidate genes have been 69 
found in <10% of the cases (4).  70 
A recent work from our group in the zebrafish model (6) demonstrated a role for Notch pathway in 71 
thyroid morphogenesis and function. Notch pathway is a highly conserved cell-to-cell 72 
communication system involved in the specification of many tissues, and its alterations have been 73 
involved in several developmental diseases (7). Several ligands, including Jagged proteins, 74 
expressed on the cell surface interact with the Notch receptors of adjacent cells. This interaction 75 
results in cleavage and subsequent translocation of the Notch receptor intracellular domain (NICD) 76 
into the nucleus, where it interacts with a variety of transcription factors and repressors to modulate 77 
the expression of specific genes (8). In particular, we found that zebrafish jag1a and jag1b, 78 
orthologous of the human JAG1 encoding one single-pass trans-membrane ligand of the Notch 79 
receptors, are expressed in the developing thyroid and individually contribute to its growth and 80 
function (6). Heterozygous JAG1 variations are known to cause Alagille syndrome type 1 (ALGS1), 81 
a multisystemic congenital disorder characterized by a highly variable involvement of liver, heart, 82 
skeleton, eye and facial defects (9). Intriguingly, both CH and ALGS1 are characterized by variable 83 
expressivity and penetrance even within familial cases (10,11).  84 
In this work, we investigated whether JAG1 gene variants might be involved in inborn thyroid 85 
defects. Therefore, we analyzed the thyroid function in a series of young ALGS1 patients carrying 86 
heterozygous JAG1 variants, and screened JAG1 coding sequence in patients with CH. The 87 
identified JAG1 variants have been functionally tested in a series of bioassays in cellular and 88 
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zebrafish models. The results here reported indicate non-autoimmune hypothyroidism as a recurrent 89 
finding among ALGS1 patients, and JAG1 loss-of-function (LOF) variations as an novel 90 
predisposing cause in the pathogenesis of congenital hypothyroidism. 91 
 92 
Materials and Methods  93 
Patients 94 
Two groups of patients were enrolled in this study:  95 
- 21 unrelated ALGS1 patients carrying non-synonymous variations in JAG1 gene that had been 96 
referred to our center for genetic diagnosis of Alagille syndrome; 97 
- 100 unrelated CH subjects (66 thyroid dysgenesis and 34 gland-in-situ).  98 
The thyroid imaging was performed with ultrasound and/or scintigraphy. The thyroid volume (TV) 99 
on ultrasound was calculated by the ellipsoid formula, as previously done (12). 100 
Genetic investigation was extended to a control group of 349 blood donors. Institutional ethical 101 
committees approved the study, and informed consent for blood sampling and genetic investigations 102 
were obtained from all participants or from parents. 103 
Experimental procedures 104 
Details on the genetic screening, bioinformatics analyses, cloning, mutagenesis and transfection of 105 
JAG1 constructs, as wells as protocols of the functional assays in vitro (cellular expression and 106 
evaluation of the differentiation potential of JAG1 variants) or in vivo in the zebrafish model 107 
(knock-down of JAG1 orthologues with morpholino antisense oligos and characterization of jag1-108 
deficient fish, rescue experiments of the phenotype of jag1-deficient fish using human JAG1 109 
variants and Notch-dependent luciferase assay) are reported in the Supplemental material. Fish were 110 
maintained and raised according to the EU (Directive 2010/63/EU) and Italian (Decreto legislativo 111 
116/92) regulations on laboratory animals, and the study was approved by the institutional ethical 112 
committee. 113 
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Statistical Analysis 114 
Statistical analyses were carried out using the software package PRISM 4.0 (GraphPad, San Diego, 115 
CA). Results are expressed as mean ± SE. Kruskal-Wallis test followed by Dunn's Multiple 116 
Comparison Test were used. All data were shown as means ± standard error (SEM) or percentages. 117 
The Mann-Whitney test and the t-student test were used to comparison of differences between 118 
groups. The p<0.05 was considered statistically significant (*p<0.05; ** p<0.01; ***p<0.001). All 119 
the analyses were conducted with the software package GraphPad Prism 4.0 (GraphPad, San Diego, 120 
CA).  121 
 122 
Results 123 
Thyroid function in ALGS1 124 
The biochemical and ultrasound investigations revealed that 6 out 21 ALGS1 patients (28.6%) have 125 
the biochemical features of non-autoimmune mild hypothyroidism (high TSH and fT4 levels in the 126 
lower part of the normal range). The thyroid imaging revealed a thyroid hypoplasia in 2 of these 127 
ALGS1 cases (Table 1). All patients had non-synonymous JAG1 variations and the clinical and 128 
genetic features typical of ALGS1, variably including chronic liver failure, congenital heart defects, 129 
facial dysmorphism, skeletal abnormalities or embriotoxon (Table 1). Inheritance of JAG1 variants 130 
could be assessed in all cases but one: the variant found in ALGS_4 occurred de novo, whereas the 131 
maternal or paternal inheritance was seen in the others. In the families, the phenotypical expression 132 
of the ALGS1 defects was highly variable among the carriers (Table 1). 133 
Genetic screening of JAG1 gene in CH patients 134 
Among 100 CH patients, we identified two distinct JAG1 sequence variants in four unrelated 135 
patients. The first missense variation, p.R937Q (rs145895196, minor allele frequency, MAF: 136 
0.0022), already described in different ALGS cases (13,14)  was found in 3 cases. The patient 137 
identified by CH1 was affected by apparent athyreosis and an atrial septal defect; the patients CH3 138 
and CH4 had an apparent athyreosis or a gland-in-situ, respectively, associated with no other 139 
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evident abnormality (Table 1). The second variant, p.R744Q (rs147809756, MAF: 0.0010) (15), 140 
was found in patient CH2 with thyroid ectopy, pulmonary artery atresia and ventricular septal 141 
defect. In all these cases, we excluded the presence of other mutations in known candidate genes 142 
(NKX2-1, FOXE1, PAX8, NKX2-5, TBX1 and SHH). Furthermore, none of these four patients 143 
showed clinical features consistent with ALGS1. In two cases, the inheritance of the variant could 144 
be assessed. The mothers of CH2 and CH4 had also non-autoimmune mild hypothyroidism (Table 145 
1). 146 
Bioinformatics analyses 147 
We identified seven different JAG1 variants, four missense changes affecting residues that are well 148 
conserved across species (Supplemental Fig 1), two causing a premature truncation of the translated 149 
protein, and one deletion affecting the donor splice site after exon 18. All variations affect 150 
functionally relevant protein domains (Supplemental Table 1). Five variations are new, whereas two 151 
had been previously reported in ALGS1 patients (13-15) and in 1000 Genomes database, and were 152 
also found in 3 out of 349 subjects of the control population (0.0086%; P=0.046 vs CH).  153 
The functional impact of the missense or truncated variants was tested by 7 online programs. The 154 
new variants p.T587I, p.C917G, p.N1026EfsX8 and p.I1035X are invariably predicted to be 155 
potentially damaging (Supplemental Table 2).  The rare variants p.R744Q and the p.R937Q are 156 
predicted to be deleterious by 4 or 2 out of 7 algorithms, respectively.  All these variants had no 157 
potential splicing effects, in contrast with the intronic deletion (IVS_18 c.2860+1 delAG) 158 
(Supplemental Table 3).  159 
Immunofluorescence localization of JAG1 variants 160 
The Jagged1 sub-localization was studied in transiently transfected NIH-3T3 cells by confocal 161 
microscopy. The immunodetection of Jagged1 ligand revealed that the wild-type protein is largely 162 
expressed on the cell membrane, and only a minor component is detectable in intracytoplasmatic 163 
compartments (Fig. 1A). The missense variants p.T587I, p.R744Q and p.R937Q are also efficiently 164 
expressed on the cell membrane, in contrast with truncated proteins (p.N1026EfsX8 and p.I1035X) 165 
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and the missense variant p.C917G, which are almost completely retained in the perinuclear region 166 
(Fig. 1A). The amount of Jagged1 protein expression was similar for all constructs (data not 167 
shown). 168 
In vitro differentiation assay 169 
The ability of Jagged1 ligand to affect the terminal differentiation of the C2C12 myoblasts is well 170 
documented (16,17). The C2C12 myoblasts cell line has been widely used as a model system of 171 
myogenesis, since the differentiation program of these cells is readily induced, easily monitored, 172 
and highly reproducible (18). When C2C12 cells are cultured in mitogen-poor medium, they 173 
differentiate into multinucleated myotubes and express muscle lineage-specific genes, such as 174 
MyoD and MRF4 (19). This differentiation program is inhibited in the presence of functional 175 
Jagged1 ligands and, indeed, the expression of these muscle differentiation genes is strongly 176 
repressed after transfection of wild-type JAG1 (Fig. 1B). At variance, the transfection of mutant 177 
constructs does not significantly affect the expression levels of MyoD and MRF4 genes, though a 178 
non significant tendency toward a reduced expression of the differentiation markers can be 179 
observed after transfection of p.T587I, p.R744Q and p.R937Q constructs. These results are 180 
therefore consistent with a loss of function (LOF) of JAG1 variants. 181 
Evaluation of the phenotype in jag1_MOs injected zebrafish embryos 182 
In order to study the in vivo effects of JAG1 variants, we took advantage of the vertebrate zebrafish 183 
model. After 24 hpf of the co-injection of jag1a and jag1b mopholinos (jag1_MO), thousands of 184 
embryos were compared with mismatch controls (mism_ctrls) and classified into three graded 185 
phenotype classes, depending on the severity of defects in the body length and  curvature. Class 1 186 
(C1_MO): mild phenotype: moderately shortened body. Class 2 (C2_MO): intermediate phenotype: 187 
shortened body and notochord abnormalities. Class 3 (C3_MO): severe phenotype: shortened body, 188 
notocord defects and twisted or truncated tail (Fig. 2A). The phenotypic classification correlates 189 
with the diminished expression of wild-type (long) jag1a and jag1b and the specular increase of 190 
aberrant (short) trancripts induced by morpholino injection (Fig. 2B-D). We performed ten 191 
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independent experiments of jag1_MO injection and distributed the embryos in the three classes with 192 
the following frequency: C1_MO: 22%; C2_MO: 63%; C3_MO: 15%. Of note, all jag1_MO 193 
embryos dysplay craniofacial abnormalities such as small head and eyes, thin midbrain-hindbrain 194 
boundary and, in 30% of cases, cardiac edema.   195 
The mism_ctrls exhibit a normal expression of early (nkx2.4b) and late (slc5a5 and tg) thyroid 196 
markers (Fig.2, panels E, I, N). Of note, the thyroid phenotype was highly homogeneous among 197 
each group (around the 90-95% of embryos) and well correlated with the severity of the defects 198 
found in jag1_MOs. At 24 hpf, the expression of nkx2.4b in the thyroid primordium was slightly 199 
reduced in the C1_MO embryos when compared with mism_ctrls (Fig. 2F), and at 48 and 72 hpf, 200 
the C1_MO embryos exhibited a negligible decrease of tg and slc5a5 staining whilst mantaining a 201 
normal thyroid shape (Fig. 2, panels J, O). In C2_MOs, a significant reduction of nkx2.4b 202 
expression at 24 hpf (Fig. 2G) is evident; the impared thyroid primordium specification is followed 203 
by a diminished expression of tg and slc5a5 at 48 and 72 hpf, and a decreased thyroid size lacking 204 
the typical elongation of the zebrafish thyroid along the ventral aorta at 72 hpf (Fig. 2, panels K, P). 205 
In C3_MOs, the thyroid primordium is absent or severly reduced all along the period of observation 206 
(Fig. 2, panels H, L, Q).  207 
To understand the level of thyroid function impairment in the different classes of jag1_MOs, we 208 
concomitantly quantified the expression tshba and tg by confocal microscopy of embryos subjected 209 
to in situ hybridization and qRT-PCR (Fig. 3). The different grades of the hypothyroid phenotype 210 
exhibited by jag1_MOs is associated with a corresponding increase in the expression of tshba gene, 211 
consistent with a primary defect of the thyroid gland. In particular, in the C2_MOs the reduced tg 212 
expression was associated with a significant increase in the expression of tshba at both 48 hpf (Fig. 213 
3, panels C and C’ and I) and at 72 hpf (Fig. 3, G and G’ and K). The severe impairment of thyroid 214 
function in C3_MOs induced a further increase of tshba expression in the thyreotrope cells at 48 215 
hpf (Fig. 3, D and D’ and I) and at 72 hpf (Fig. 3, H and H’ and M).                                                                                                                         216 
After confocal evaluation, forty embryos from each pool were used for qRT-PCR analysis (Fig 3, J 217 
de Filippis et al., 10 
and L). These data confirmed those obtained by confocal microscopy at 48 and 72 hpf.  218 
Rescue of thyroid function with hJAG1 constructs 219 
In order to evaluate the effects of the hJAG1 variants on thyroid function in vivo, we co-injected the 220 
purified human transcripts with the morpholinos against the zebrafish jag1a and jag1b. After five 221 
indipendent experiments, we splitted the thousands of embryos into two major groups: group 1 (G1, 222 
rescued morphological phenotype and normal tg expression): correct body length, null/slight 223 
notochord and craniofacial defects and normal thyroid phenotype; group 2 (G2, unreverted 224 
phenotype/ hypothyroidism as seen in C2_ and C3_MOs): reduced body length, moderate/severe 225 
notochord and craniofacial defects and reduced size of tg expression (Fig. 4, Panels A-L). The 226 
volume of tg positive cells was similar in G1 or G2 classes, through all conditions (Fig. 4N). 227 
The injection of human  JAG1_WT transcript is associated with a normal phenotype and thyroid 228 
function in 75% of the cases, resulting in a rescue efficiency of 55% (percent increase of G1 229 
embryos over jag1_MOs); these embryos dysplay a significant improvement of tg expression 230 
reaching values similar to those of the mism_ctrls (Fig. 4M).  The co-injection of missense  231 
p.T587I, p.R744Q and p.R937Q transcripts are able to significantly revert the morphological and 232 
hypothyroid phenotype (+29%, +35% and + 25% of G1 embryos, respectively), but these rescue 233 
efficiencies were significantly lower than that of wild-type trascript. Finally, the injection of the 234 
p.C917G mRNA leads to a rescue efficiency of only 13% (p=NS vs jag1_MOs), while the truncated 235 
forms (p.N1026EfsX8 and p.I1035X) always failed to revert the jag1_MO phenotype (Fig. 4M).  236 
In vivo zebrafish luciferase assay 237 
An in vivo dual-luciferase assay was used to investigate the ability of the JAG1 variants to interact 238 
with Notch receptors and activate the downstream intracellular signals. The zebrafish embryos were 239 
co-injected with a luciferase reporter gene construct (pGa981-6-Firefly), containing the 240 
hexamerized NICD-responsive RBP-Jk binding motif, and growing amount of different JAG1 241 
constructs. We co-injected the same amount of the pGa981-6-Firefly in the presence of growing 242 
concentrations (2.5-50 pg/embryo) of the pcDNA3.2/V5-DEST JAG1_WT. The activity of the 243 
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Firefly luciferase is strictly dependent upon the amount of the JAG1_WT injected reaching the 244 
plateau at 40-50 pg/embryo, and the concentration of 25 pg/embryo was chosen to analyze the 245 
JAG1 variants (Fig. 5A). In agreement with the rescue experiment, the missense JAG1 variants are 246 
only partially able to activate the NICD-responsive elements in vivo, with a significant impairment 247 
of luciferase activity induction when compared to the wild-type construct (p.R744Q: 70%; p.T587I 248 
and  p.R937Q: 56%; p.C917G: 42% of JAG1_WT). The truncated constructs (p.N1026EfsX8 and 249 
p.I1035X) displayed a complete loss of the ability to enhance the expression of luciferase (Fig. 5, 250 
B). 251 
Discussion 252 
This is the first report that provides evidence for the association between Notch signaling defects 253 
and congenital thyroid disorders in humans.  254 
In a cohort of young patients with clinical manifestations and genetic analyses consistent with 255 
Alagille syndrome type 1, we found biochemical data indicating a non-autoimmune hypothyroidism 256 
in 28% of the cases. In addition, we found that JAG1 variants with partial LOF are significantly 257 
enriched among CH patients. In association with evidence obtained in the vertebrate model 258 
zebrafish, these data indicate the JAG1 gene as an additional candidate involved in the pathogenesis 259 
of congenital thyroid defects.  260 
Here, we describe 7 different JAG1 LOF variants, 5 of which never reported. These variants were 261 
analyzed by several in silico prediction algoritms, and in vitro or in vivo bioassays. The missense 262 
variations fall in the EGF-like repeats or the cysteine rich (CR) domains that are relevant for 263 
Jagged1 function and interaction with Notch receptors. In particular, the p.C917G change may alter 264 
the protein conformation and is in fact associated with a poor membrane targeting, similar to that 265 
seen with the truncated variants. Differently, the intronic deletion at the donor site of intron 18 266 
(IVS18 c.2860+1delAG) was not tested in vitro, but the in silico analysis performed with ad hoc 267 
predictive programmes indicates this deletion as highly deleterious. In addition, this variation co-268 
segregated with the disease phenotype in the family ALGS_3. Consistent with the known 269 
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involvement of JAG1 in the pathogenesis of ALGS, the heterozygous JAG1 variations with a more 270 
severe or complete LOF are associated with ALGS1 phenotype, whereas CH is associated with two 271 
rare missense variants previously reported in ALGS1 (13-15) and here characterized by a partial 272 
LOF.  273 
Since hypothyroidism has not been previously reported in Alagille syndrome, this could be 274 
explained by the severe clinical picture affecting most ALGS patients that may mask the clinical 275 
signs of a mild hypothyroid state. On the other hand, ALGS is also associated with manifestations 276 
(growth retardation in 87%, mental retardation in 2%) (20) that might indeed be worsened by 277 
untreated hypothyroidism. Our data therefore raise the need for evaluation of thyroid disorder in 278 
larger cohorts of ALGS1 patients  because of an increased risk of thyroid dysfunction. 279 
These clinical findings are consistent with data obtained in the zebrafish model (6). Here, we 280 
provide further evidence that the knock-down of jag1-notch signaling in zebrafish causes primary 281 
hypothyroidism due to a defective thyroid growth, and other developmental defects, that can be 282 
rescued by injection of human  JAG1 transcripts supporting the specificity of the morpholinos. 283 
Evidences obtained by characterizing thousands of fishes (Fig. 4) show that the rare variants 284 
associated with CH are defective in either the rescue experiments or in vivo luciferase bioassay,  as 285 
well as  in the in vitro studies. The different phenotypic classes described upon jag1a/jag1b 286 
inactivation could be the result of either stochastic biological events or unpreventable small 287 
variations in the amount of morpholinos contained in each injected drop, emphasizing the fine gene-288 
dosage sensitivity of the developing embryos. The morphological defects of our jag1_MO embryos 289 
(craniofacial and notochord alterations and, infrequently, cardiac edema) are similar to the ones 290 
described in other reports (21-23). In particular, we observed cardiac defects (unlooped heart tube 291 
formation) in less than 30% of jag1_MO embryos from 72 to 120 hpf. We found that several steps 292 
of thyroid morphogenesis are affected in jag1_MOs: at 24 hpf the nkx2.4b expression is absent or 293 
significantly reduced, and in these latter cases the residual thyroid follicles fail to elongate along the 294 
ventral aorta at 48-72 hpf. The hypothyroid phenotype induced by a defective Jagged1-Notch signal 295 
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both in humans and zebrafish could at least partially result from a direct effect limiting the number 296 
of thyroid precursors reaching the differentiated state, as jag1a and jag1b had been previously 297 
reported to be expressed in the developing thyroid follicles (6), but a contribution of defective 298 
signals coming from the surrounding tissues (such as the developing heart or big vessels) is also 299 
plausible. Interestingly, 3 out of 4 CH cases with JAG1 variations had a dysgenetic thyroid 300 
(apparent athyreosis/profound hypoplasia or ectopy) associated with congenital heart defects in two 301 
of them (in the absence of variations in other candidate genes for these complex CH phenotypes), 302 
suggesting  a more likely involvement of JAG1 variants in CH cases associated with thyroid 303 
dysgenesis and/or heart malformations.  304 
Both ALGS1 and CH are diseases characterized by a variable expression and penetrance, consistent 305 
with the different phenotype recorded in the relatives of the probands, and confirming that still 306 
unknown mechanisms are likely to contribute to the clinical expression of JAG1 gene defects. 307 
These mechanisms should however be multiple and different in ALGS1 versus CH, since JAG1 308 
variants with similar LOF can be seen in both diseases. Still undetermined alterations affecting the 309 
Notch signal or thyroid function are more likely to coexist with JAG1 variations in ALGS1 or CH 310 
families, respectively. Consistently, homozygous Jagged1 mutant mice died at E9.5-10.5 of 311 
widespread haemorrhage (24), while heterozygous Jagged1 mutant mice developed mild ocular 312 
defects, and only the specific combinations of jagged/notch gene knockdowns in zebrafish or mice 313 
were able to perturb the biliary, kidney, pancreas and craniofacial development as in Alagille 314 
syndrome (22,24,25). Similarly, the study of double heterozygous Pax8 and Titf1 null mice (26) has 315 
recently confirmed the existence of modifier alleles and the importance of gene dosage in the 316 
pathogenesis of CH.  317 
In conclusion, the whole of the clinical and experimental data indicate that ALGS1 patients have an 318 
increased risk of non-autoimmune hypothyroidism, and that heterozygous variations in JAG1 gene 319 
represent a novel predisposing event contributing to the pathogenesis of congenital thyroid defects.  320 
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Figure Legends 402 
 403 
Figure 1. Panel A, sub-cellular localization of wild-type and mutant Jagged-1 proteins in 404 
NIH3T3 cell lines. Proteins were visualized by immunofluorescence with a monoclonal anti-405 
Jagged-1 antibody (1C4, Cell Signaling Technology) followed by Alexa Fluor 488 conjugated 406 
secondary antibody (green signal). DNA was counterstained with DAPI (blue signal). Cell 407 
membranes were labelled with Alexa Fluor 594-tagged wheat germ agglutinin (WGA, red). Panel 408 
B, Inhibition of muscles-specific gene expression by JAG1 variants. C2C12 cells were 409 
transiently transfected with the different constructs. After incubation in DM for three days, total 410 
RNA was extracted and the expression level of MyoD and MRF4 were analysed by qRT-PCR. 411 
Samples were normalized using the ß-actin expression as housekeeping gene. The CT method 412 
was used to calculate relative expression levels, Empty vector_DM sample was used as calibrator. 413 
Statistically significant (*p< 0.05; ***p<0.0001) performed with Kruskal-Wallis test followed by 414 
Dunn's Multiple Comparison Test. 415 
 416 
Figure 2. Panel A, Morphological classification of jag1_MO embryos. Jag1_MO were analyzed 417 
at 24 hpf and subdivided in three major classes, based on body length and curvature. From the left 418 
to right: mismatch controls (mism_ctrls); Class 1 (C1_MO): mild phenotype: normal or slight 419 
curved tail; Class 2 (C2_MO) intermediate phenotype: shortened body, curved tail and notochord 420 
defects (arrowheads); Class 3 (C3_MO) severe phenotype: severely reduced body length, twisted 421 
tail, notochord defects. In the bottom left: number of embryos for each phenotype. Lateral views, 422 
anterior to the left. Scale bar: whole embryo 500 m. Panel B-D, Evaluation of jag1a and jag1b 423 
mRNA expression of injected embryos. Panel B: jag1a and jag1b pre-mRNA and mRNA 424 
structures resulted from co-injection of jag1a (E2i2) and jag1b (E3i3) morpholinos (jag1_MOs):  425 
squared boxes indicate the exon, the black lines correspond to the introns. The position of the 426 
primers used to analyze the altered splicing by RT-PCR or qRT-PCR is indicated by blue arrows. 427 
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Panel C: RT_PCR of jag1a and jag1b mRNAs in jag1_MOs. The 500 bp and 320 bp PCR products 428 
were obtained in the mism_ctrls for jag1a and jag1b, respectively; at variance,  jag1_MOs injected 429 
embryos display a reduction of the wt form and the presence of shorter products in both cases. 430 
Interestingly, the phenotypic classes of jag1_MOs nicely correlate with the amount of the wt/short 431 
expressed transcript. The beta-actin gene was used as a reference gene. The sequence analysis of the 432 
shorted products reveals the partial skipping of the E2 into the jag1a and the complete E3 skipping 433 
into the jag1b mRNAs. Panel D: qRT-PCR of jag1a and jag1b mRNAs expression after 434 
morpholinos injection using different sets of primers (indicated by the blue arrows in Panel B) that 435 
discriminate between the wild-type and shorter products. Results are expressed as % between the 436 
absolute quantification of the wt or short PCR products of jag1a or jag1b. The eef1a was used as 437 
housekeeping gene. Similar transcriptional effects were obtained when jag1a and jag1b 438 
morpholinos had been injected separately (6). Consistently with the semi-quantitative RT-PCR, the 439 
phenotype of jag1_MOs correlates with the ratio of the wt/short mRNAs. Panel E-Q, Evaluation 440 
of thyroid development on jag1_MO embryos. Whole mount in situ hybridization showing 441 
nkx2.4b (corresponding to human NKX2.1), slc5a5 and tg transcripts in representative jag1_MOs 442 
and control fish at 24, 48 and 72 hpf. For each marker, 50 embryos of mism_ctrls and from each 443 
class of jag1_MOs were analyzed. Images in ventral view, anterior to the left. (E, I and N) 444 
mismatch controls (mism_ctrls) exhibit a normal expression of early (nkx2.4b) and late (slc5a5 and 445 
tg) thyroid markers. (F, G and O) Class1 of jag1_MO (C1_MO): slight reduction of thyroid marker 446 
expression with normal thyroid differentiation at 48 and 72hpf. (G, K and P); Class2 of jag1_MO 447 
(C2_MO): significant reduction of nkx2.4b, slc5a5 and tg expression, with a markedly reduced 448 
thyroid size at 72 hpf. (H, L and Q); Class3 of jag1_MO (C3_MO): severe reduction/undetectable 449 
levels of nkx2.4b, slc5a5 and tg. Failure of thyroid primordium formation and thyrocyte 450 
differentiation at 72 hpf. Scale bar: (E-H) 50 m, (I-Q) 20 m. 451 
 452 
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Figure 3. Expression of tshba and tg in jag1_MOs. The induced expression of tshba 453 
(corresponding to human TSHβ) by the pituitary due to the defective thyroid gland in jag1_MOs, is 454 
consistent with a primary defect in jag1_MOs. Images of WISH/Fast Blue staining followed by 455 
confocal acquisition of tshba and tg in C1_MOs (B and B’, F and F’), C2_MOs (C and C’, G and 456 
G’) and C3_MOs (D and D’, H and H’) at 48 and 72 hpf, compared with mism_ctrls (A and A’, E 457 
and E’). Embryos are all flat mounted, in ventral view, with anterior to the top. Histograms I and K 458 
summarize results from quantification of total tshba- and tg-positive cell volume (mm3) at 48 and 459 
72 hpf, using confocal microscope analysis on the same region and number of sections for each 460 
embryo (20 embryos for each stage and phenotype). Graphs J and L show the tshba and tg 461 
expression analysed by qRT-PCR at 48 and 72 hpf, compared with mism_ctrls. Asterisks indicate 462 
statistically significant differences (Mann-Whitney test, *p<0.05 and **p<0.001). 463 
 464 
Figure 4. Panel A-F, Phenotypic features of the rescued embryos coinjected with jag1a and 465 
jag1b morpholinos and the human JAG1 mRNAs. At 24 hpf, phenotype of mism_ctrls (A and D) 466 
in comparison to: group1_embryos (B and E) with reverted phenotype and normal/slight reduced 467 
body length, normal craniofacial development; group2_embryos (C and F) with not reverted 468 
phenotype and reduced body length/ curved tail, notochord and craniofacial defects. Lateral views, 469 
anterior to the left. Scale bar: whole embryo 500 m, head 200 m. Panel H-L, expression by 470 
WISH of tg in the G1 and G2 embryos and comparison with the mism_ctrls at 72 hpf. Images in 471 
lateral view (G-I) or in ventral view (J-L). Scale bar 200 m and 50 m, respectively. Panel M, 472 
histograms show the percentage of embryos inside the group 1 (G1) and group 2 (G2) at 24 hpf 473 
after injection of jag1_MO only, or jag1_MO plus 7.5 pg/embryo of human JAG1_WT or mutant 474 
mRNAs, as indicated. Panel N, consistently to the WISH experiment, the histograms show the 475 
normal tg expression in G1 and the defective tg expression in G2 embryos under the different 476 
conditions (injection as in Panel M). Results of tg volume (mm3) are expressed as mean ± SD. 477 
*p<0.05 and **p<0.001, indicate statistically significant differences versus the jag1_MOs. #p<0.05 478 
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and ##p<0.001, indicate statistically significant differences between mutant and wild-type 479 
JAG1mRNAs.  480 
 481 
 482 
Figure 5. Zebrafish luciferase assay of JAG1_WT and variant constructs. Panel A, Co-483 
injection with the same amount of pGa981-6-Firefly plus pcDNA3.2/V5-DEST (empty) as negative 484 
control or JAG1_WT, at growing concentrations (2.5-50 pg/embryos). The relative luciferase 485 
activity (RLU) was calculated by normalization with the Renilla pRL-TK levels (Firefly/Renilla). 486 
Panel B, Co-injection of 25 pg/embryo of pGa981-6-Firefly with pcDNA3.2/V5-DEST or 487 
JAG1_WT and JAG1_variants. The luciferase activity (RLU) of hJAG1 variants was compared to 488 
the wild type form. Asterisks indicate statistically significant differences versus JAG1_WT (Mann-489 
Whitney test, *p<0.05 and **p<0.001). 490 
 Table 1. Clinical features of ALGS1 patients and CH infants with JAG1 variants. 
 
Case 
Sex/Age* 
JAG1 variant dbsTSH 
(mU/L) 
Serum 
TSH 
(mU/L) 
Serum FT4 
(% of the 
lower limit 
of normal)§ 
Thyroid 
imaging 
Other defects Inheritance of genetic variant 
and phenotype in carriers 
ALGS_1
M/11 yrs 
p.R937Q <10 22.0 127 Hypoplasia 
(4.6 mL) 
TGV, single heart 
ventricle, chronic liver 
failure and cholestasis, 
growth retardation 
Paternal (no ALGS1 features in the 
family, father TSH 2.1 mU/L) 
ALGS_2 
M/25 yrs 
p.T587I <20 4.3 113 n.a VSD and coarctation of 
the aorta, typical facial 
dysmorphism, cholestasis 
Paternal (father with reminiscent 
facial dysmorphisms, TSH 5.4 
mU/L) 
ALGS_3 
M/3 yrs 
IVS_18 
c.2860+1 
delAG 
<10 7.2 120 GIS  
(4.4 mL) 
Persistent atrial septal 
defect, embryotoxon, 
butterfly vertebrae 
Paternal (JAG1 variant co-
segregated with ALGS1 phenotype 
in father and elder brother; TSH 
n.a.) 
ALGS_4 
F/10 yrs 
p.N1026EfsX8 <10 5.6 140 GIS  
(6 mL) 
Pulmonary artery stenosis, 
bile duct paucity, butterfly 
vertebrae 
de novo (no ALGS1 features in the 
family) 
ALGS_5 
M/21 yrs 
p.C917G <20 9.7 136 n.a Right ventricle hypoplasia, 
pulmonary artery atresia, 
posterior embryotoxon, 
mild cholestasis, absent 
gallbladder 
Maternal (no ALGS1 features in 
the family) 
ALGS_6 
M/6 yrs 
p.I1035X n.a 15.3 105 Hypoplasia 
(2 mL) 
Chronic cholestasis, 
typical facial 
dysmorphism, VSD 
n.a. 
CH1 
F/3 wks 
p.R937Q >100 245 60 Apparent 
athyreosis^ 
Atrial septal defect Paternal (TSH n.a.) 
CH2 
F/2 wks 
p.R744Q >100 812 13 Lingual 
ectopy 
VSD and pulmonary artery 
atresia 
Maternal (mother TSH 6.1 mU/L) 
Table 1 Click here to download Table Table 1.docx 
CH3 
F/2 wks 
p.R937Q >100 >500 27 Apparent 
athyreosis^ 
none n.a. 
CH4 
M/3 wks 
p.R937Q 12 10.7 80 GIS none n.a. (mother TSH 4.8 mU/L) 
 
Note: M, male; F, female; * at the diagnosis of hypothyroidism; yrs, years; wks, weeks; § normal values in ng/dL: 1.5-2.4 for infants, 0.9-2.0 for 
pre-pubertal children, 0.7-1.7 for adults; dbs, dry blood spot; TGV, transposition of the great arteries; VSD, ventricular septal defect; GIS, gland-in-
situ; ^, gland not visible at scintiscan, but profound hypoplasia at ultrasound associated with detectable thyroid hormone in serum; n.a.; not 
available. 
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